Acceso usuarios
Diane S. Aschenbrenner
* Golimumab, a monoclonal antibody, has been approved to treat moderate-to-severe ulcerative colitis in adults who've been resistant to prior treatment or who need continuous steroid therapy.
* Because of the immune suppression from golimumab, patients receiving the drug are at increased risk for serious infections.
